Stephen Fritz, MD
Allergy & Immunology · Happy Valley, ORNPI 1881799963
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (42.9%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 21.7%. Reporting peaked in 2019 at $18,947 and has fallen 81.6% since, to $3,485 in 2025. Among allergy & immunology clinicians in OR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 799 payments — averaging $52.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$9K
- Shire North American Group Inc$5K
- Pharming Healthcare, Inc.$5K
- Takeda Pharmaceuticals U.S.A., Inc.$3K
- Biocryst Pharmaceuticals, Inc.$3K
- AstraZeneca$3K
- plus $14K from 30 others
Across 59 payments — averaging $3936.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$68K
- Hikma Pharmaceuticals USA$52K
- Aimmune Therapeutics, Inc.$42K
- Regeneron$23K
- AstraZeneca$15K
- Pfizer$15K
- plus $17K from 4 others
What the payments were for
- Consulting fees$8,48820%
- Speaking & faculty fees$12,21029%
- Travel & lodging$2,7477%
- Food & beverage$17,84943%
- Education$2721%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 120 | $9,002 |
| Shire North American Group Inc | 16 | $4,847 |
| Pharming Healthcare, Inc. | 30 | $4,633 |
| Takeda Pharmaceuticals U.S.A., Inc. | 50 | $3,241 |
| Biocryst Pharmaceuticals, Inc. | 12 | $3,055 |
| AstraZeneca | 113 | $2,672 |
| GSK | 140 | $2,536 |
| Biocryst US Sales Co., LLC | 27 | $1,786 |
| Grifols USA, LLC | 13 | $1,416 |
| Regeneron Healthcare Solutions, Inc. | 53 | $1,395 |
| Cycle Pharmaceuticals Inc | 4 | $1,319 |
| Novartis | 43 | $844 |
| Sanofi | 26 | $715 |
| Pfizer | 31 | $709 |
| Kaleo, Inc. | 24 | $628 |
| Genentech USA, Inc. | 30 | $602 |
| Blueprint Medicines Corporation | 11 | $354 |
| Amgen | 13 | $312 |
| Boehringer Ingelheim | 8 | $235 |
| Organon | 1 | $169 |
| Phathom Pharmaceuticals, Inc. | 2 | $155 |
| ADMA Biomanufacturing LLC | 2 | $137 |
| Teva Pharmaceuticals USA, Inc. | 5 | $127 |
| Octapharma USA, Inc. | 1 | $102 |
| Verona Pharma, Inc. | 3 | $82 |
| Alk-abello, Inc | 4 | $70 |
| Ionis Pharmaceuticals, Inc. | 2 | $69 |
| Lilly USA, LLC | 2 | $62 |
| Sanofi-aventis U.S. LLC | 1 | $61 |
| Mylan Specialty L.p. | 3 | $55 |
| Galderma Laboratories, L.p. | 2 | $53 |
| Philips North America LLC | 2 | $34 |
| Optinose US, Inc. | 2 | $33 |
| Jubilant Hollisterstier LLC | 1 | $24 |
| Greer Laboratories, Inc. | 1 | $22 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$41,566 in reported general payments places this provider in the 90th percentile of 33 allergy & immunology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 33 | $135,880 |
| Dupixent SyringeDupilumab | 17 | $92,191 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 39 | $55,067 |
| Spiriva RespimatTiotropium Bromide | 38 | $29,861 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 47 | $29,397 |
| Epinephrine | 52 | $12,614 |
| Breo ElliptaFluticasone/Vilanterol | 29 | $10,283 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 43 | $6,821 |
| DuleraMometasone/Formoterol | 20 | $6,549 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 29 | $6,074 |
| Advair HfaFluticasone Propion/Salmeterol | 16 | $5,959 |
| Wixela InhubFluticasone Propion/Salmeterol | 18 | $3,243 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 65 | $1,763 |
| Montelukast Sodium | 160 | $1,731 |
| Levalbuterol Tartrate HfaLevalbuterol Tartrate | 11 | $836 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringHizentra | $9,002 | $55,06739 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $2,536 | $39,68076 claims |
| Boehringer IngelheimSpiriva Respimat | $235 | $29,86138 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 33 allergy & immunology providers in Oregon.
Other allergy & immunology in Happy Valley
- Adam WilliamsBend$138K
- Shyam JoshiPortland$116K
- Anthony MontanaroPortland$25K
- Karen AnsteyPortland$20K
- Michael OsbornePortland$11K
- Jessica MacdougallPortland$11K
- Kraig JacobsonEugene$7K
- James SweetTualatin$7K
- Benjamin RahoySalem$5K
- Maxwell LiEugene$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.